Skip to content
Home/Companies/Biotech/ExcellGene
ExcellGene

ExcellGene

Biotech·Switzerland·Active·1yr hold
Entry
2025
Hold
1yr
Status
Active

Who owns ExcellGene?

ExcellGene is a Swiss Biotech company, currently owned by ARCHIMED since 2025.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
ARCHIMED
Investor
ARCHIMED
MED Rise · 2024 · Buyout

Key facts

HQSwitzerland
SectorBiotech
Websiteexcellgene.com

More from MED Rise

Other portfolio companies in the same fund.

IRAB
IRAB
Active
PharmaSpain· 2026
Renata Medical
Active
MedTechUnited States· 2026
Agatha
Active
HealthTechJapan· 2025
Arkstone
Active
HealthTechUS· 2025
Ceva
Ceva
Active
PharmaFrance· 2025
Ceva Animal Health
Ceva Animal Health
Active
PharmaFrance· 2025

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns ExcellGene?

ExcellGene is currently owned by ARCHIMED, through MED Rise, since 2025.

When did ARCHIMED acquire ExcellGene?

ARCHIMED acquired ExcellGene in 2025.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue